RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Clinical trials for RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo fights back against Tough-to-Treat lung cancer
Disease control OngoingThis study is testing whether combining two drugs, durvalumab and lurbinectedin, can help control a fast-growing type of lung cancer that has returned or stopped responding to standard treatments. It aims to see if this combination can help patients live longer without their canc…
Matched conditions: RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Scientists test Triple-Threat attack on Tough-to-Treat lung cancer
Disease control OngoingThis early-stage study is testing the safety and best dose of a new three-drug combination for small cell lung cancer that has returned after initial treatment. The combination includes a pill (tazemetostat), a chemotherapy (topotecan), and an immunotherapy (pembrolizumab), aimin…
Matched conditions: RECURRENT EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC